Empresa Veloxis Pharmaceuticals A/S CBOE EUROPE EQUITIES
Acciones
0IVI
DK0060048148
Farmacéuticos
Precio de cierre
Otros sitios de cotización
|
||
- DKK | - |
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Stacy Wheeler
COO | Chief Operating Officer | - | 01/03/16 |
Chief Tech/Sci/R&D Officer | - | 13/09/17 | |
Lionel Rostaing
PRN | Corporate Officer/Principal | - | - |
Josep Grinyo
PRN | Corporate Officer/Principal | - | - |
Noel Barnard
LAW | General Counsel | - | 01/03/16 |
Mark Hensley
PRN | Corporate Officer/Principal | - | 01/04/16 |
Rita L. Mannella
HRO | Human Resources Officer | - | 01/01/17 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 1 739 741 590 | 173 932 405 ( 9,998 %) | 0 | 9,998 % |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Asahi Kasei Corp., Veloxis Pharmaceuticals, Inc. manufactures pharmaceuticals for kidney transplant patients. The company is based in Edison, NJ. |
Pharmaceuticals: Major
|
Sector
Varia. 1 de ene. | Capi. | |
---|---|---|
+16,03 % | 79,03 mil M | |
+10,23 % | 8957,25 M | |
-10,76 % | 5185,62 M | |
+51,58 % | 4767,65 M | |
+12,50 % | 4262,16 M | |
-20,70 % | 2368,86 M | |
+12,83 % | 2295,01 M | |
-29,65 % | 2208,65 M | |
+19,51 % | 2172,8 M |
- Bolsa de valores
- Acciones
- Acción VELO
- Acción 0IVI
- Empresa Veloxis Pharmaceuticals A/S